There are 2934 resources available
Presentation of case/condition
Presenter: John Haanen
Session: Toxicity profiling of immunotherapy of cancer
Resources:
Slides
Webcast
Managing patients with irAEs unresponsive to corticosteroids
Presenter: Camillo Ribi
Session: Toxicity profiling of immunotherapy of cancer
Resources:
Slides
Webcast
5443 - Harmonization study of Tumour Mutational Burden determination in Non-Small-Cell Lung Cancer (NSCLC)
Presenter: Eva M Garrido-Martin
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
Poster Discussion – Genitourinary tumours, prostate - Invited Discussant LBA50, 845PD, 846PD and 847PD
Presenter: Elena Castro
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Slides
Webcast
1085 - CCTG IND 232: A Phase II Study of Durvalumab With or Without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Sebastien Hotte
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
1612 - Efficacy and Safety of Nivolumab in Combination With Docetaxel in Men With Metastatic Castration-Resistant Prostate Cancer in CheckMate 9KD
Presenter: Karim Fizazi
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
Poster Discussion – Genitourinary tumours, prostate - Invited Discussant LBA51, LBA52, 848PD, 849PD and 855PD
Presenter: Cora Sternberg
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Slides
Webcast
5387 - Health-related quality of life (HRQL) in a randomized phase 3 trial of enzalutamide with standard first line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial
Presenter: Martin Stockler
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
5435 - TCR-beta repertoire convergence and evenness are associated with response to immune checkpoint inhibitors
Presenter: Philip Jermann
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
3307 - Switch Maintenance Gemcitabine After First Line Chemotherapy In Patients With Malignant Mesothelioma; A Multicenter Open Label Phase II Trial (NVALT19)
Presenter: Sjaak Burgers
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract